Pharming Group N.V. (PHAR) — SEC Filings

Latest SEC filings for Pharming Group N.V. (PHAR), explained in plain English.

Sentiment Overview: 5 bullish, 37 neutral

Recent Filings (42)

• 6-K Filing — 6-K · 2026-04-02T06:10:50-04:00 [neutral]
• Pharming's Revenue Jumps 18.5% on Strong Ruconest, Joenja Sales — 20-F · 2026-04-02T06:03:01-04:00 [bullish] Risk: medium
  Pharming Group N.V. reported a significant increase in revenue to $245.7 million for the fiscal year ended December 31, 2025, up 18.5% from $207.3 million in 20
• 6-K Filing — 6-K · 2026-03-27T07:35:54-04:00 [neutral]
• Pharming Group N.V. Files 6-K with Press Release — 6-K · 2025-11-06T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on November 6, 2025, to furnish a press release dated November 6, 2025. The press release is included as Exhibit 99.1 to th
• Pharming Group N.V. Files 6-K with October Press Release — 6-K · 2025-10-22T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on October 22, 2025, furnishing a press release dated October 20, 2025. The filing is related to the month of October 2025
• Pharming Group N.V. Files Form 6-K — 6-K · 2025-10-06T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on October 6, 2025, to furnish a press release dated October 6, 2025. The filing does not contain specific financial figure
• Pharming Group N.V. Files 6-K with Press Release — 6-K · 2025-10-01T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on October 1, 2025, to furnish a press release dated October 1, 2025. The filing itself does not contain specific financial
• Pharming Group N.V. Files 6-K with Press Release — 6-K · 2025-09-10T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on September 10, 2025, to furnish a press release dated September 10, 2025, as Exhibit 99.1. The filing does not contain sp
• Pharming Group Appoints New Supervisory Board Member — 6-K · 2025-09-02T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. announced on September 2, 2025, the appointment of Kenne as a new member of its Supervisory Board. Kenne brings extensive experience in the
• Pharming Group N.V. Files 6-K for Q2 Results — 6-K · 2025-07-31T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on July 31, 2025, to furnish a press release regarding its second quarter financial results. The press release, dated July
• Pharming Group to Host Financial Results Webcast — 6-K · 2025-06-24T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. announced on June 24, 2025, that it will host a webcast to discuss its financial results and business updates. The webcast is scheduled for
• Pharming Group N.V. Files 6-K with June Press Release — 6-K · 2025-06-11T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on June 11, 2025, to furnish a press release dated the same day. The filing is for the month of June 2025 and indicates tha
• Pharming Group N.V. Files 6-K with Press Release — 6-K · 2025-05-08T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on May 8, 2025, to furnish a press release dated May 8, 2025. The filing itself does not contain specific financial figures
• Pharming Group N.V. Files 6-K with Press Release — 6-K · 2025-04-30T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on April 30, 2025, to furnish a press release dated April 30, 2025. The press release, filed as Exhibit 99.1, is the primar
• Pharming Group N.V. Files Form 6-K with Press Release — 6-K · 2025-04-25T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. announced on April 25, 2025, that it is furnishing a press release as Exhibit 99.1 to its Form 6-K filing. The press release details are not
• Pharming Group's Leniolisib Gets CHMP Positive Opinion — 6-K · 2025-04-23T00:00:00.000Z [bullish] Risk: medium
  Pharming Group N.V. announced on April 23, 2025, that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) regardin
• 20-F Filing — 20-F · 2025-04-03T00:00:00.000Z [neutral]
• Pharming Group N.V. Reports Q1 2025 Results — 6-K · 2025-03-20T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. announced its first quarter 2025 financial results on March 20, 2025. The company, headquartered in Leiden, The Netherlands, is a pharmaceut
• Pharming Group N.V. Files 6-K with March 13 Press Release — 6-K · 2025-03-13T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on March 13, 2025, furnishing a press release dated March 13, 2025, as Exhibit 99.1. The filing is for the month of March 2
• Pharming Group N.V. Files Form 6-K — 6-K · 2025-03-04T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on March 4, 2025, to furnish a press release dated the same day. The filing does not contain specific financial figures or
• Pharming Group N.V. Files 6-K with Press Release — 6-K · 2025-02-20T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on February 20, 2025, to furnish a press release dated February 20, 2025. The filing is made under the Securities Exchange
• Pharming Group N.V. Files Form 6-K with Press Release — 6-K · 2025-02-07T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on February 7, 2025, to furnish a press release dated February 7, 2025, as Exhibit 99.1. The filing does not contain specif
• Pharming Group N.V. Files 6-K with Press Release — 6-K · 2025-01-21T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on January 21, 2025, to furnish a press release dated January 21, 2025, as Exhibit 99.1. The filing does not contain specif
• Pharming Group to Acquire NovaThera for $150M — 6-K · 2024-12-16T00:00:00.000Z [bullish] Risk: medium
  Pharming Group N.V. announced on December 15, 2024, that it has entered into a definitive agreement to acquire all of the outstanding shares of NovaThera Inc. f
• Pharming Group's C1-INH Deficiency Drug Shows Positive Phase III Results — 6-K · 2024-12-11T00:00:00.000Z [bullish] Risk: medium
  Pharming Group N.V. announced positive top-line results from its Phase III clinical trial for leniolisib for the treatment of C1 esterase inhibitor deficiency (
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-11-08T00:00:00.000Z [neutral]
• Pharming Group N.V. Files Form 6-K — 6-K · 2024-10-24T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on October 24, 2024, to furnish a press release dated October 24, 2024. The filing itself does not contain specific financi
• Pharming Group N.V. Files 6-K with Press Release — 6-K · 2024-10-10T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on October 10, 2024, to furnish a press release dated the same day as Exhibit 99.1. The filing does not contain specific fi
• Pharming Group inks US marketing deal for RUCONEST® — 6-K · 2024-09-26T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. announced on September 26, 2024, that its subsidiary, Pharming Healthcare Inc., has entered into a marketing and distribution agreement with
• Pharming Group N.V. Files 6-K with Press Release — 6-K · 2024-08-01T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on August 1, 2024, to furnish a press release dated August 1, 2024. The filing itself does not contain detailed financial i
• Pharming Group N.V. Files 6-K with Press Release — 6-K · 2024-05-30T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on May 30, 2024, to furnish a press release dated May 30, 2024. The filing itself does not contain specific financial figur
• Pharming Group N.V. Files Form 6-K — 6-K · 2024-05-21T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on May 21, 2024, to furnish a press release dated May 21, 2024, as Exhibit 99.1. The filing does not contain specific finan
• Pharming Group N.V. Files Form 6-K with Press Release — 6-K · 2024-05-15T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on May 15, 2024, to furnish a press release dated the same day. The press release, filed as Exhibit 99.1, likely contains i
• Pharming Group N.V. Files 6-K with Press Release — 6-K · 2024-05-08T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on May 8, 2024, to furnish a press release dated May 8, 2024. The filing itself does not contain specific financial figures
• Pharming Group N.V. Files 6-K with April Press Releases — 6-K · 2024-04-25T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on April 25, 2024, to furnish press releases dated April 18-19, 2024, as Exhibits 99.1, 99.2, and 99.3. The filing is for t
• Pharming to Acquire Pharming Healthcare for $100M — 6-K · 2024-04-24T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. announced on April 24, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of its subsidiary, Pharming H
• Pharming Group N.V. Files 6-K with Press Release — 6-K · 2024-04-08T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on April 8, 2024, to furnish a press release dated April 8, 2024, as Exhibit 99.1. The filing does not contain specific fin
• Pharming Group N.V. Files 2023 Annual Report — 20-F · 2024-04-04T00:00:00.000Z [neutral] Risk: medium
  Pharming Group N.V. filed its 20-F for the fiscal year ending December 31, 2023. The company, based in Leiden, Netherlands, operates in the pharmaceutical prepa
• Pharming Group N.V. Files 6-K for Q4 2023 Update — 6-K · 2024-03-14T00:00:00.000Z [neutral] Risk: low
  Pharming Group N.V. filed a Form 6-K on March 14, 2024, to furnish a press release dated the same day as Exhibit 99.1. The filing does not contain specific fina
• SC 13G Filing — SC 13G · 2024-02-14T00:00:00.000Z [neutral]
• Pharming Ups 2023 Guidance: RUCONEST® Revenue Jumps 10%, Joenja® Hits $18M — 6-K · 2024-01-08T00:00:00.000Z [bullish]
  Pharming Group N.V. announced updated full-year 2023 guidance on January 8, 2024, projecting a significant 10% growth in RUCONEST® revenue, which is much higher